1. Home
  2. ENTO
  3. ENTO News

Latest Entero Therapeutics Inc. Common Stock (ENTO) News on June 30, 2025

Entero Therapeutics Announces Signing of Rescission Agreement with ImmunogenX, LLC
ENTO

Newsfile

3 months ago

Entero Therapeutics Announces Signing of Rescission Agreement with ImmunogenX, LLC

Entero Therapeutics Appoints Richard Paolone as CEO
ENTO

GlobeNewswire

4 months ago

Entero Therapeutics Appoints Richard Paolone as CEO

Entero Therapeutics Secures $2 Million Revolving Loan; Appoints Three New Board Members
ENTO

GlobeNewswire

5 months ago

Entero Therapeutics Secures $2 Million Revolving Loan; Appoints Three New Board Members

Entero Therapeutics CEO James Sapirstein to Moderate the 2024 BioFlorida Annual Innovation Conference CEO Forum
ENTO

GlobeNewswire

8 months ago

Entero Therapeutics CEO James Sapirstein to Moderate the 2024 BioFlorida Annual Innovation Conference CEO Forum

Entero Therapeutics Announces Proposed Reverse Merger with Journey Therapeutics, A Clinical Stage, First-in-Class, Next-Generation ADC-rivalling Nano-immunoconjugates Biopharmaceutical Company
ENTO

GlobeNewswire

8 months ago

Entero Therapeutics Announces Proposed Reverse Merger with Journey Therapeutics, A Clinical Stage, First-in-Class, Next-Generation ADC-rivalling Nano-immunoconjugates Biopharmaceutical Company

Entero Therapeutics Signs Letter of Intent to License and Commercialize Remote Patient and Machine Vision Clinical Trial Management Platform from Data Vault Holdings
ENTO

GlobeNewswire

10 months ago

Entero Therapeutics Signs Letter of Intent to License and Commercialize Remote Patient and Machine Vision Clinical Trial Management Platform from Data Vault Holdings

Entero Therapeutics, Inc. Receives Nasdaq Notification Regarding Delayed Form 10-Q
ENTO

GlobeNewswire

10 months ago

Entero Therapeutics, Inc. Receives Nasdaq Notification Regarding Delayed Form 10-Q

Entero Therapeutics’ Chairman and CEO James Sapirstein Provides Business Update with Focus on Latiglutenase Development Program
ENTO

GlobeNewswire

a year ago

Entero Therapeutics’ Chairman and CEO James Sapirstein Provides Business Update with Focus on Latiglutenase Development Program

Entero Therapeutics Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.9 Million Gross Proceeds
ENTO

GlobeNewswire

a year ago

Entero Therapeutics Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.9 Million Gross Proceeds

Entero Therapeutics Announces Abstract on Celiac Disease Research Accepted for Presentation at the 20th International Celiac Disease Symposium
ENTO

GlobeNewswire

a year ago

Entero Therapeutics Announces Abstract on Celiac Disease Research Accepted for Presentation at the 20th International Celiac Disease Symposium

Entero Therapeutics Announces Peer-Reviewed Publication Unveiling Novel Algorithm for Measuring Intestinal Damage in Celiac Disease
ENTO

GlobeNewswire

a year ago

Entero Therapeutics Announces Peer-Reviewed Publication Unveiling Novel Algorithm for Measuring Intestinal Damage in Celiac Disease

Share on Social Networks: